AIM ImmunoTech Inc.

AIM XASE • BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Historical Short Interest Share

American Express® Business Gold Card

Earn Up to 200K Membership Rewards® Points

4X on your top 2 spending categories. Transfer to 20+ airline & hotel partners. Terms apply.

Learn More

Market Cap

6.9M

Short interest (Jul 15)

5.6%

Net Short (Jul 27 ): 0.1%

Borrow Fee

74.81%

↓ 19.9%

Available Shares

↑ 12.3%

Price Chart

Company Overview

AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).

Company Info

Exchange: XASE

Industry: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

CIK: 0000946644

Asset Type: CS

Market Data

Market Cap: $6,903,337

Employees: 21

Status: Active

Short Interest

Current Borrow Fee 74.81%

Range: 72.73% - 80.89%

Available Shares 1M

Range: 1M - 1.3M

Recent Changes

Fee Change: ↓ 16.2%

Available Change: ↓ 4.2%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime